Login / Signup

Evidence summaries and recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome: assessment and treatment of infertility.

M F CostelloM L MissoA BalenJ BoyleL DevotoHelena J TeedeR HartL JohnsonC JordanR S LegroR J NormanE MocanuJ QiaoR J RodgersL RombautsE C TassoneS ThangaratinamE Vankynull null
Published in: Human reproduction open (2019)
The guideline was primarily funded by the Australian National Health and Medical Research Council of Australia (NHMRC) supported by a partnership with ESHRE and the American Society for Reproductive Medicine (ASRM). GDG members did not receive payment. Travel expenses were covered by the sponsoring organizations. Disclosures of conflicts of interest were declared at the outset and updated throughout the guideline process, aligned with NHMRC guideline processes. Dr Costello has declared shares in Virtus Health and past sponsorship from Merck Serono for conference presentations. Prof. Norman has declared a minor shareholder interest in the IVF unit Fertility SA, travel support from Merck and grants from Ferring. Prof. Norman also has scientific advisory board duties for Ferring. The remaining authors have no conflicts of interest to declare.This article was not externally peer-reviewed by Human Reproduction Open.
Keyphrases
  • polycystic ovary syndrome
  • healthcare
  • insulin resistance
  • endothelial cells
  • public health
  • type diabetes
  • pregnant women
  • health information
  • skeletal muscle
  • risk assessment
  • replacement therapy